Whole Genome Amplification Market By Product & Service (Kits & Reagents, Instruments, Services); By Technology (Multiple Displacement Amplification [MDA], Degenerate Oligonucleotide-Primed PCR [DOP-PCR], Primer Extension Preamplification [PEP], Other Technologies); By Application (Single-Cell Genomics, Next-Generation Sequencing [NGS], Genetic Disease Research, Forensic Analysis, Preimplantation Genetic Testing, Other Applications); By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical & Diagnostic Laboratories, Forensic Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Whole Genome Amplification Market: Single-Cell Genomics, PGT and High-Throughput Sequencing Are Turning WGA Into Core Genomic Workflow Infrastructure  – (Updated On: 18-Aug-2026)

The Global Whole Genome Amplification Market was valued at USD 0.61 billion in 2025 and is projected to reach USD 1.00 billion by 2032, expanding at a CAGR of 7.3% during 2026–2032.

 

Whole Genome Amplification (WGA) is a molecular technique designed to produce a large quantity of DNA from a very small starting sample. It is particularly valuable when the available genetic material is limited, such as DNA obtained from a single cell, a tiny biopsy, or a forensic specimen. By increasing the amount of genomic DNA, WGA makes it possible to perform downstream analyses such as DNA sequencing, genotyping, and disease-related genetic studies.

 

Several approaches have been developed for whole genome amplification. Multiple Displacement Amplification (MDA) is an isothermal method that relies on phi29 DNA polymerase and random primers. The enzyme can synthesize long stretches of DNA with relatively high accuracy while displacing previously formed strands, allowing amplification to continue without repeated temperature cycling. MDA is therefore widely used when long DNA products and good sequence fidelity are important.

 

Degenerate Oligonucleotide-Primed PCR (DOP-PCR) is a PCR-based approach. It uses partially random primers that can attach at many locations throughout the genome. Initial amplification occurs under conditions that allow the primers to bind broadly, followed by conventional PCR cycles that increase the amount of DNA. This method can work with limited or partially degraded material, although amplification may not be equally efficient across every genomic region.

 

Another PCR-based technique is Primer Extension Preamplification (PEP). PEP uses short random primers to initiate DNA synthesis at numerous positions across the genome. It was one of the earlier methods developed for analyzing DNA from individual cells. Although it can generate sufficient material for further testing, uneven amplification and loss of one allele at some genetic locations can limit its accuracy.

 

Multiple Annealing and Looping-Based Amplification Cycles (MALBAC) was developed to improve the uniformity of amplification, particularly in single-cell studies. During the early stages, newly produced DNA molecules form loop-shaped structures that reduce their likelihood of being repeatedly copied. This helps prevent certain regions from becoming excessively amplified and can provide more balanced genome coverage.

 

In general, a WGA procedure begins with a very small quantity of DNA. The DNA is made accessible for primer binding, primers initiate synthesis at many locations, and polymerase enzymes generate numerous copies of the genomic material. Depending on the method, amplification may occur at a constant temperature or through repeated temperature cycles. The resulting amplified DNA can then be used for applications such as whole-genome sequencing, mutation analysis, genotyping, or other molecular tests.

 

WGA has become especially useful in single-cell genomics, where only a tiny amount of DNA is naturally available. It also has applications in forensic science, where biological evidence may be scarce or degraded, and in medical and cancer research, where researchers may need to investigate DNA from small tissue samples or rare cell populations.

 

Despite its usefulness, WGA does not create a perfectly identical representation of the original genome. Amplification bias can cause some genomic regions to be copied more efficiently than others. Allele dropout can occur when one version of a gene is successfully amplified while the other is not detected. Contamination is another important concern because even a small amount of unwanted DNA can become highly amplified along with the intended sample. For this reason, careful sample preparation, appropriate controls, and selection of a suitable WGA method are important for obtaining reliable results.

 

Overall, WGA provides a practical solution when the quantity of genomic DNA is too small for direct analysis. MDA, DOP-PCR, PEP, and MALBAC achieve this goal through different amplification strategies, and each method has particular strengths and limitations. The most appropriate technique depends on factors such as DNA quality, the amount of starting material, the type of genetic analysis being performed, and the level of genome coverage and accuracy required.

 

What Are the Key Segments of the Whole Genome Amplification Market?

By Product & Service

Kits & Reagents accounted for the largest share of the Whole Genome Amplification Market in 2025 at 63.0%, equivalent to USD 0.384 billion, and are projected to grow at a CAGR of 7.0% during 2026–2032. Their dominance reflects continuous use across MDA, PCR-based amplification, single-cell sequencing, PGT and other low-input genomic workflows, where enzymes, primers and buffers must be repeatedly replenished.

Instruments represented 20.0% of the market, valued at USD 0.122 billion in 2025, and are projected to expand at a CAGR of 6.4%. Demand is driven by automated liquid handling, thermal cycling and integrated sequencing preparation systems, with slower growth reflecting longer replacement cycles and higher upfront costs.

Services accounted for 17.0% of the market, or USD 0.104 billion in 2025, and are forecast to grow at the fastest rate within the segment, at a CAGR of 9.3%. Outsourced amplification, single-cell sequencing, library preparation and bioinformatics are increasingly used by organizations that lack in-house infrastructure or require scalable capacity.

 

By Technology

Multiple Displacement Amplification [MDA] led the technology segment with 46.0% of the market, equivalent to USD 0.281 billion in 2025, and is projected to grow at a CAGR of 7.7%. Its dominance reflects strong adoption in single-cell and low-input workflows due to Phi29 polymerase-based high-fidelity, long-fragment DNA amplification.

Degenerate Oligonucleotide-Primed PCR [DOP-PCR] accounted for 23.0% of the market, valued at USD 0.140 billion in 2025, and is projected to grow at a CAGR of 6.5%. It remains relevant in established copy-number and genotyping workflows where simplicity and compatibility with standard PCR systems are prioritized.

Primer Extension Preamplification [PEP] represented 15.0% of the market, or USD 0.092 billion in 2025, with a projected CAGR of 5.8%. Its use is stable but increasingly limited as higher-fidelity and more uniform amplification methods gain traction.

Other Technologies accounted for 16.0% of the market, valued at USD 0.098 billion in 2025, and are expected to grow at a CAGR of 8.4%. This includes emerging and hybrid methods designed to reduce bias and improve performance in single-cell and long-read sequencing applications.

 

By Application

Single-Cell Genomics was the largest application segment at 28.0%, equivalent to USD 0.171 billion in 2025, and is projected to grow at a CAGR of 8.7%. It relies on WGA for analyzing individual cells in cancer research, developmental biology and rare-cell studies.

Next-Generation Sequencing [NGS] accounted for 25.0%, valued at USD 0.153 billion in 2025, and is expected to grow at a CAGR of 8.0%. WGA is essential for preparing low-input samples for sequencing and library construction.

Genetic Disease Research represented 18.0%, or USD 0.110 billion in 2025, and is projected to grow at a CAGR of 6.5%. It supports analysis of limited or degraded DNA in inherited and rare disease studies.

Forensic Analysis accounted for 11.0%, valued at USD 0.067 billion in 2025, and is forecast to grow at a CAGR of 5.4%. Adoption is constrained by strict requirements for contamination control and reproducibility.

Preimplantation Genetic Testing represented 10.0%, equivalent to USD 0.061 billion in 2025, and is projected to grow at a CAGR of 6.9%. It is a key use case due to the extremely low DNA input from embryo biopsies.

Other Applications accounted for 8.0%, valued at USD 0.049 billion in 2025, and are expected to grow at a CAGR of 5.0%. These include microbial, environmental and archival DNA analysis.

Single-cell genomics and NGS remain the leading applications because they directly depend on amplification of extremely limited DNA inputs.

 

By End User

Academic & Research Institutes held the largest share at 39.0%, equivalent to USD 0.238 billion in 2025, and are projected to grow at a CAGR of 6.5%. They use WGA across broad research areas including cancer genomics, developmental biology and single-cell studies.

Pharmaceutical & Biotechnology Companies accounted for 26.0%, valued at USD 0.159 billion in 2025, and are expected to grow at the fastest rate, at a CAGR of 8.7%. Demand is driven by drug discovery, biomarker research and cell and gene therapy development.

Clinical & Diagnostic Laboratories represented 23.0%, or USD 0.140 billion in 2025, and are projected to grow at a CAGR of 7.7%. WGA is embedded in validated workflows for reproductive genetics, PGT and specialized molecular diagnostics.

Forensic Laboratories accounted for 12.0%, valued at USD 0.073 billion in 2025, and are expected to grow at a CAGR of 5.6%. Use is limited to cases involving highly degraded or minimal DNA samples.

 

Why Is Whole Genome Amplification Demand Expanding Faster Than Conventional DNA Preamplification?

Growth is driven by increasing reliance on very low-input and rare biological samples, where conventional DNA preparation is not feasible. WGA enables analysis of single cells, embryo biopsies and microdissected tissues that cannot be expanded or recollected.

The expansion of NGS has reinforced this need, as sequencing platforms require high-quality input DNA even when starting material is extremely limited. As a result, WGA is increasingly embedded within end-to-end cell-to-library workflows rather than used as a standalone step. For example, QIAGEN’s QIAseq Single Cell DNA Library Kit integrates lysis, MDA and library preparation, supporting up to 384 samples per flow-cell lane, while its UPX format enables up to 576 multiplexed samples, improving throughput and reducing handling.

This shift is also changing procurement behavior. Smaller laboratories tend to purchase standalone kits, while larger genomics centers and pharmaceutical companies prioritize integrated workflows with automation, indexing and sequencing compatibility.

Public initiatives such as the NIH SMaHT Network are further increasing demand for higher accuracy and lower bias amplification, particularly for rare variant detection in single-cell studies.

Overall, the market is shifting from maximizing DNA yield toward improving data fidelity in single-cell genomics.

 

Why Does Multiple Displacement Amplification Remain the Leading WGA Method?

MDA remains dominant because it produces long, high-fidelity DNA fragments using Phi29 polymerase under isothermal conditions. It is widely used in single-cell and low-input workflows due to its strong genome coverage and accuracy.

However, it can produce uneven coverage and allele dropout in single-cell applications, which limits its precision in some high-resolution studies.

DOP-PCR and PEP continue to be used in simpler, cost-sensitive applications such as copy-number analysis, where uniform long-fragment coverage is less critical.

Newer methods are expanding the landscape. Takara Bio’s PicoPLEX v3 uses quasi-linear preamplification for CNV and SNV analysis in very low cell numbers, while Primary Template-directed Amplification (PTA) from BioSkryb focuses on reducing bias and improving single-cell accuracy, with automation-ready 384-well formats.

MDA remains the standard for broad genome recovery, while newer methods are gaining share in high-precision single-cell applications.

 

Why Is Preimplantation Genetic Testing One of the Clearest Commercial WGA Applications?

PGT is one of the most established real-world uses of WGA because embryo biopsies provide only a few cells, requiring reliable genome-wide amplification before analysis.

The ESHRE PGT Consortium (2019–2021) reported 14,731 PGT analyses, with WGA-linked genome-wide analysis used in 99% of PGT-A cases and 74% of combined PGT-M/SR plus PGT-A cases. This confirms that WGA is a standard step in embryo genetic testing workflows.

Demand is supported by large-scale fertility activity. The CDC reported 435,426 ART cycles in the U.S. in 2022, while the UK HFEA recorded over 100,000 treatment and freezing cycles in 2024.

However, adoption is influenced by reimbursement and clinical evidence. HFEA notes that PGT-A is not NHS-funded and does not improve live-birth rates for most patients, which limits uptake. In contrast, PGT-M is NHS-commissioned for specific genetic conditions, supporting a smaller but more stable patient base.

 

Why Is Single-Cell Genomics Becoming the Most Strategically Important WGA Growth Area?

Single-cell genomics is driving the most advanced WGA requirements because it demands accurate detection of SNVs, CNVs and structural variation from a single genome copy.

Companies are responding with higher-throughput and lower-bias systems. BioSkryb’s ResolveDNA platform supports up to 384 reactions per kit, and its collaboration with Tecan enables automated 384-well workflows. Its ResolveSEQ long-read program reports 75–92% genome coverage and over 70% SNV detection sensitivity in early-access testing.

The NIH SMaHT initiative is also funding technologies for improved single-cell variant detection, reinforcing demand for more accurate amplification methods.

This is particularly important in cancer research, where tumor heterogeneity requires sequencing of individual cells to identify subclonal variation that bulk sequencing cannot resolve.

 

How Are Kits, Reagents and Integrated Library Systems Changing WGA Procurement?

Kits and reagents remain the core revenue driver, accounting for 63.0% of the market (USD 0.384 billion in 2025), due to continuous consumption across all major applications.

Pricing is typically contract-based. For example, QIAGEN’s REPLI-g Single Cell Kit (24 reactions) is listed at about USD 865, while Illumina and MilliporeSigma products are generally sold through institutional agreements, making real pricing highly variable.

A key trend is workflow integration, where amplification is combined with library preparation and sequencing readiness. QIAGEN, Illumina and BioSkryb all offer integrated systems that reduce handling steps and improve efficiency.

Automation is also becoming essential as laboratories scale to higher throughput. Plate formats, liquid-handling compatibility and sequencing success rates are increasingly important, shifting demand toward reproducible, automation-ready WGA systems rather than standalone reagents.

 

How Do Clinical Regulation and Molecular-Diagnostics Reimbursement Affect WGA Suppliers?

Much of the WGA product market remains research-use-only rather than a stand-alone regulated diagnostic market. QIAGEN explicitly states that its REPLI-g and QIAseq single-cell products are intended for molecular-biology applications and not for diagnosis, prevention or treatment. NEB similarly markets its WGA reagents for research use.

Commercialization therefore frequently occurs through a validated downstream laboratory workflow rather than reimbursement for “WGA” as an independent medical procedure.

CMS billing guidance illustrates this structure in the United States. Medicare molecular-pathology policy focuses on molecular pathology procedures, genomic sequencing procedures and clinically necessary tests. Coverage can depend on analytical validity, clinical utility and whether test results directly affect patient management.

Market interpretation: WGA chemistry is generally an upstream analytical input whose cost is absorbed into a broader molecular or genomic test rather than a separately reimbursed clinical event. Consequently, a WGA supplier's economics depend heavily on becoming specified inside validated laboratory-developed tests, sequencing workflows or commercial assay systems.

This favors companies that provide documentation, automation protocols, downstream compatibility and reproducibility data in addition to polymerase chemistry.

 

Why Do Regional Dynamics Matter in the Whole Genome Amplification Market?

Why North America Remains Central to High-Value WGA Adoption

North America combines large sequencing infrastructure, biomedical research funding, pharmaceutical R&D and a substantial reproductive-medicine sector, accounting for 38.0% of the market, equivalent to USD 0.232 billion, and is projected to grow at a CAGR of 6.6%. The CDC's 435,426 U.S. ART cycles in 2022 illustrate the scale of the fertility ecosystem, while NIH programs such as SMaHT are creating research demand for progressively more accurate single-cell genomic workflows.

The region is important for premium single-cell adoption due to commercialization of emerging WGA technologies through U.S. genomics labs and sequencing providers, including BioSkryb’s automated 384-well and long-read workflows, while Vitrolife’s Q1 2025 PGT-A revenue growth in the Americas signals strong reproductive-genetics demand; however, the previously cited North American market value is excluded as it is inconsistent with the revised USD 0.61 billion global baseline and the 42.3% share should be treated as an unverified assumption pending recalculation.

 

Europe’s Importance in PGT-Linked WGA Demand

Europe provides the strongest publicly documented evidence connecting WGA directly with PGT, accounting for 26.0% of the market, valued at USD 0.159 billion in 2025, and projected to grow at a CAGR of 6.8%, with the ESHRE PGT Consortium finding WGA-linked genome-wide analysis in 99% of reported PGT-A analyses for 2019–2021, establishing the technique as an entrenched laboratory step in this application.

The UK illustrates how regulation influences adoption, with HFEA reporting rising PGT-A use alongside scrutiny of its clinical value and a decline in NHS-funded IVF cycles from 35% in 2019 to 28% in 2024, increasing reliance on private fertility services, while broader European WGA demand remains strong but highly sensitive to evidence standards, reimbursement structures and embryo-testing regulations.

 

Strategic Importance of Asia-Pacific Despite an Unverified Leading Regional Share

Asia-Pacific has a large and expanding reproductive-medicine and genomics ecosystem, accounting for 25.0% of the market (USD 0.153 billion) with a CAGR of 9.3%, but the supplied 38.5% regional-share estimate should not be presented as the leading global share without reconciling it against the separate 42.3% North American assumption.

Japan and Australia–New Zealand report high ART cycle volumes (over 561,000 and 112,000 in 2023 respectively), while Asia-Pacific also hosts key WGA players like Takara Bio, making its importance driven by strong reproductive medicine demand, growing genomics research, and local biotech manufacturing rather than a precise global market share.

 

Factors Shaping WGA Adoption in Latin America, the Middle East and Africa

These markets are more heterogeneous. Demand is concentrated around academic sequencing centers, tertiary hospitals, private reproductive-genetics laboratories and international research collaborations rather than uniformly distributed high-throughput genomics infrastructure. Latin America accounts for 6.0% of the market, valued at USD 0.037 billion, and is projected to grow at a CAGR of 7.4%, while the Middle East & Africa represents 5.0% of the market, valued at USD 0.031 billion, with a projected CAGR of 6.5%.

Commercial performance in these regions is highly sensitive to import costs, distribution strength, equipment access and currency fluctuations, with companies like Vitrolife showing weaker results in Latin America despite stronger North American demand, meaning WGA adoption tends to concentrate in well-equipped reference and major genomics laboratories rather than routine settings.

 

Who Are the Key Players Shaping the Competitive Landscape in the Whole Genome Amplification Market?

QIAGEN’s Competitive Position in the Whole Genome Amplification Market

QIAGEN has one of the broadest commercial WGA positions through its REPLI-g MDA chemistry and increasingly integrated single-cell sequencing products. The REPLI-g Single Cell Kit supports amplification from single cells and limited DNA samples, while QIAseq Single Cell DNA Library products combine lysis, MDA and NGS library preparation. The standard QIAseq platform supports up to 384 samples in a flow-cell lane, while the UPX workflow can process hundreds of samples through pooled libraries.

Its competitive advantage is therefore not merely Phi29 chemistry. QIAGEN is attempting to capture more of the workflow between isolated cell and sequence-ready library.

 

Illumina’s Position in Reproductive Genomics

Illumina participates through SurePlex, a single-cell DNA amplification system closely associated with embryo-biopsy and PGT research workflows. SurePlex is supplied in a 50-reaction format, accepts single- or multi-cell input and generates amplified DNA suitable for downstream genomic analysis.

Illumina's strategic advantage comes from its sequencing ecosystem. WGA that feeds directly into sequencing and cytogenomic applications can strengthen consumable attachment to the broader NGS platform rather than compete as an isolated reagent.

 

Takara Bio's Importance in PCR-Based and Hybrid Single-Cell WGA

Takara Bio competes through PicoPLEX Single Cell WGA Kit v3. The platform is designed for one to ten mammalian cells or very small DNA inputs and uses quasi-random preamplification followed by amplification. Takara positions the current generation for CNV and SNV analysis and automation.

The portfolio is strategically relevant because it provides laboratories with an alternative to conventional MDA, particularly where consistent copy-number representation and streamlined single-cell processing are priorities.

 

BioSkryb as an Important Emerging Competitor in the Whole Genome Amplification Market

BioSkryb Genomics differentiates itself through PTA rather than conventional MDA or DOP-PCR. ResolveDNA is available at up to 384 reactions per kit, while the company's Tecan partnership brings cell dispensing, WGA and library preparation into an automated high-throughput workflow.

Its 2025 expansion into single-cell long-read sequencing is particularly important strategically. If high-coverage long-read analysis from single cells becomes reproducible at scale, WGA suppliers will compete for applications that conventional short-read single-cell DNA sequencing has difficulty addressing, including complex structural variants, repeat regions and phased genomic changes.

 

Thermo Fisher Scientific's Role in the WGA Ecosystem

Thermo Fisher Scientific competes through Phi29 and enhanced Phi29 enzyme products used for MDA-WGA and through its wider molecular-biology and sequencing ecosystem. The company identifies MDA as the most widely used WGA technique and markets Phi29-based products for amplification from very small DNA quantities.

Its strength is broad laboratory penetration: WGA enzymes can be incorporated into customized research workflows rather than requiring customers to adopt a single proprietary end-to-end kit.

 

MilliporeSigma’s Position in PCR-Based Whole Genome Amplification

MilliporeSigma/Merck maintains the GenomePlex Single Cell Whole Genome Amplification portfolio. GenomePlex fragments genomic DNA and converts those fragments into PCR-amplifiable library molecules before universal-primer amplification. The system has been applied to CNV, STR, SNP and circulating-tumor-cell research.

Its continued availability demonstrates that PCR-based WGA has not disappeared despite MDA's broader leadership. Established workflows, familiar protocols and compatibility with specific downstream assays preserve a commercial niche.

 

Analyst Perspective: What Could Materially Restrain the Whole Genome Amplification Market?

Whole genome amplification (WGA) is limited mainly by its tendency to distort the original DNA signal. In single-cell applications, even small errors such as uneven amplification or allele dropout can significantly affect results, and these issues cannot be corrected through deeper sequencing. Another major challenge is contamination, since WGA can also amplify unwanted environmental or reagent DNA, making strict contamination control essential in commercial kits.

In clinical and diagnostic settings, most WGA kits are still classified as research-use-only, meaning laboratories must fully validate the entire workflow before adoption. This slows clinical uptake because regulatory compliance and reliability are as important as performance. In preimplantation genetic testing (PGT), WGA is widely used, but growth is influenced by reimbursement policies and clinical debate, such as UK guidance noting limited evidence for improved live birth rates with PGT-A and lack of NHS funding.

Looking ahead, the WGA market is expected to grow from USD 0.61 billion in 2025 to USD 1.00 billion by 2032, driven by more advanced single-cell analysis, workflow integration, and automation. Companies are increasingly combining amplification with library preparation and sequencing workflows to improve efficiency. While MDA remains the dominant method, newer approaches like PTA and improved preamplification are gaining traction, especially where higher accuracy in single-cell genomic analysis is required.

 

Whole Genome Amplification Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.61 Billion
Revenue Forecast in 2032	USD 1.00 Billion
Overall Growth Rate	CAGR of 7.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product & Service, By Technology, By Application, By End User, By Geography
By Product & Service	Kits & Reagents, Instruments, Services
By Technology	Multiple Displacement Amplification [MDA], Degenerate Oligonucleotide-Primed PCR [DOP-PCR], Primer Extension Preamplification [PEP], Other Technologies
By Application	Single-Cell Genomics, Next-Generation Sequencing [NGS], Genetic Disease Research, Forensic Analysis, Preimplantation Genetic Testing [PGT], Other Applications
By End User	Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical & Diagnostic Laboratories, Forensic Laboratories
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of single-cell genomics and low-input sequencing workflows; increasing use of WGA in preimplantation genetic testing [PGT] and rare-cell analysis; growing integration of amplification with NGS library preparation, automation, and high-throughput workflows; rising demand for higher-fidelity and lower-bias genome amplification technologies
Customization Option	Available upon request